Prognostic Value of Microvessel Density in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

Table 1

Characteristics of the eligible studies of MVD and HNSCC.

Author	Year	Country	Median/mean age	(F/M)	Clinical stage	Location	Antibody	Evaluation of high MVD	Quality score
Chien [44]	2005	China	55.2	73 (1/72)	II-IV	HP	CD105	11.94/MPF	8
Toyoda [45]	2015	Japan	68	70 (9/61)	III/IV	HP	CD34	13/HPF	7
Xia [46]	2014	China	60	87 (38/49)	I-IV	OC	CD105	19/MPF	8
Shao [47]	2008	China	—	59 (24/35)	I-IV	OC	CD34	80/MPF	6
Marioni [48]	2011	Italy	72.2	57 (5/52)	I-IV	L	CD105	IL	7
Teppo [49]	2003	Finland	67	100 (15/85)	I-IV	L	CD31	9.6/HPF	8
Martone [50]	2005	Italy	60.8	127 (5/122)	I-IV	OC, OP, L	CD105	20.2/MPF	8
Foote [51]	2004	USA	—	123 (34/89)	I-IV	NP	F8	60/MPF	7
Calvin [52]	2007	USA	—	450 (96/354)	III/IV	OC, OP, HP, L	F8	60/MPF	7
Ito [53]	2001	Japan	61	43 (13/30)	III/IV	OC, OP, HP, L	CD31	30/MPF	6
Tastekin [54]	2015	Turkey	59.48	46 (10/36)	I-IV	OP	CD34	IL	7
Aebersold [55]	2002	Switzerland	57	95 (23/72)	I-IV	OP	CD31	IL	8
Evans [56]	2018	USA	61	200 (70/130)	I-IV	OC, OP, L	CD31	PFS:53/HPF; OS:39.667/HPF	6
Kyzas [57]	2006	Greece	64.5	108 (20/88)	I-IV	OC, L	CD105	49/MPF	6

F: female; M: male; OC: oral cavity; HP: hypopharynx; OP: oropharynx; NP: nasopharynx; L: larynx; F8: factor VIII; IL: intensity level; MPF: ×200 magnification field; HPF: ×400 magnification field.